Daily Pharma News - 6 October 2026

Cough Syrup Warning India: CDSCO Recommends Red Label Warning for Children Under 4

India's Central Drugs Standard Control Organisation (CDSCO) has taken a decisive step towards paediatric medicine safety. At its Drugs Consultative Committee (DCC) meeting on 29 September, the committee recommended a statutory red label warning on cough syrups stating they shall not be used in children below four years of age. It also proposed banning infant, toddler and toy imagery on cough syrup packaging, after the Directorate General of Health Services (DGHS) flagged rampant prescribing and self-medication of these syrups in infants.

This move comes against the backdrop of earlier controversies over contaminated cough syrups exported from India. For pharmacy students, this is a textbook lesson in pharmacovigilance and labelling regulations under the Drugs and Cosmetics Rules - statutory warnings are among the strongest regulatory tools a drug authority can deploy. It also reinforces the counselling role of pharmacists in discouraging irrational cough syrup use in young children.

Camizestrant India: CDSCO Panel Nods AstraZeneca Breast Cancer Drug Import

The Subject Expert Committee (SEC) of CDSCO has permitted AstraZeneca Pharma India to import and market Camizestrant 75 mg film-coated tablets for hormone receptor-positive, HER2-negative (HR+/HER2-) locally advanced or metastatic breast cancer carrying an ESR1 mutation. The panel waived the requirement for a local Phase III clinical trial, citing unmet medical need, while mandating a Phase IV post-marketing study.

Camizestrant is a next-generation selective oestrogen receptor degrader (SERD), a class of endocrine therapy designed to overcome ESR1-mutation-driven resistance to earlier treatments. For pharmacy students in India, this decision illustrates how CDSCO balances accelerated access to oncology innovation against evidence requirements - waiver of local trials for unmet-need drugs is a recurring regulatory theme worth tracking for exams and practice alike.

Mercury Antiseptics Ban India: DCC Mulls Curbs on Mercurochrome and Merbromin

India may soon phase out mercury-based topical antiseptics such as mercurochrome (Merbromin). The Drugs Consultative Committee is weighing a proposal to discontinue the manufacture, import and export of mercury-added antiseptics, and has sought the DGHS's views on their safety profile and clinical need. India is a signatory to the Minamata Convention on Mercury, whose exemption for such products ran until 2025.

Mercury compounds carry well-documented risks of systemic toxicity and environmental contamination, and safer antiseptics such as povidone-iodine and chlorhexidine are widely available. This is a strong example of international environmental treaties shaping domestic drug regulation - a topic that sits at the intersection of pharmaceutical chemistry, toxicology and health policy that pharmacy curricula increasingly emphasise.

Cancer Drug Pricing Karnataka: State Flags Up to 52x Hospital Markups, Seeks DPCO Reform

Karnataka's Food Safety and Drug Administration has uncovered startling price gaps: hospitals in the state were billing patients between 10 and 52 times the procurement cost on 253 high-cost drugs and consumables, including cancer medicines. The state health minister has written to the Union Health Minister seeking amendments to the Drugs (Prices Control) Order (DPCO), regulation of trade margins, and mandatory cost-to-MRP transparency on hospital bills.

Drug pricing and affordability remain among the most contested issues in Indian healthcare. The DPCO, administered by the National Pharmaceutical Pricing Authority (NPPA), caps prices of scheduled formulations - but hospital billing markups on non-scheduled drugs often escape control. For pharmacy students, this story connects pharmaceutical jurisprudence with health economics: trade-margin rationalisation is a policy tool every future pharmacist should understand.

Novartis Abogen Deal: $7.8 Billion mRNA-Encoded Therapy Pact with China

Novartis has signed a landmark agreement with China's Abogen Biosciences worth up to $7.8 billion - $575 million upfront - for exclusive rights to ABO2203, an mRNA-encoded therapy that instructs the patient's own body to produce a T-cell-engaging protein targeting harmful B cells, aimed at blood cancers and autoimmune diseases. The deal underlines how mRNA platforms are expanding far beyond vaccines into oncology and immunology.

For Indian pharmacy students, the significance is twofold: it shows the scale of global biopharma deal-making, and it highlights a therapeutic modality - in vivo protein expression via mRNA - that is likely to reshape future formularies and pharmacology syllabi. China's biotech sector, through companies like Abogen, is now a deal partner of choice for multinational pharma.

FDA Digital Therapeutic: Motivista Cleared as First Authorised Treatment for Negative Schizophrenia Symptoms

The US Food and Drug Administration has granted 510(k) clearance to Click Therapeutics' Motivista (CT-155), a prescription digital therapeutic indicated for negative symptoms of schizophrenia - low motivation, anhedonia and social withdrawal - as an adjunct to outpatient care in clinically stable adults. It is the first authorised treatment for this indication, which has long lacked effective pharmacological options.

Prescription digital therapeutics (PDTs) are an emerging regulatory category at the interface of software and medicine, reviewed by FDA's device pathways rather than as drugs. Pharmacy students should note how the definition of "therapy" is expanding: future pharmacists may counsel patients on app-based treatments alongside conventional medicines, raising new questions about adherence, data privacy and reimbursement.

Pirtobrutinib FDA Approval: Jaypirca Approved for Previously Untreated CLL/SLL

On 2 October 2026, the US FDA approved pirtobrutinib (Jaypirca, Eli Lilly), a non-covalent Bruton's tyrosine kinase (BTK) inhibitor, for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion. The approval, announced through FDA's oncology approval notifications, extends the drug's use beyond its earlier relapsed and refractory indications.

Non-covalent BTK inhibitors like pirtobrutinib were developed to overcome resistance mutations that limit covalent BTK inhibitors such as ibrutinib - a classic medicinal chemistry story of second-generation drug design. CLL is among the most common adult leukaemias, and this first-line approval gives haematologists a new targeted option, a development directly relevant to pharmacology and clinical pharmacy study.

Conclusion

Today's pharma news spans the full arc of the profession - from CDSCO's paediatric cough syrup warning and the possible phase-out of mercury antiseptics, to landmark drug approvals like Camizestrant for breast cancer in India and pirtobrutinib for CLL in the United States. Alongside Karnataka's push for fair cancer drug pricing, a $7.8 billion mRNA deal, and the first digital therapeutic for negative schizophrenia symptoms, the message for pharmacy students is clear: regulation, innovation and affordability move together. Staying current with these developments sharpens both exam preparation and the clinical judgement the profession demands.

References

← All daily news